Table 4 Medication at baseline and at 24 months
Pure Mania | Mixed episode | |||||
|---|---|---|---|---|---|---|
Baseline n = 504 | Treatment of the episode | 24 Months n = 364 | Baseline n = 262 | Treatment of the episode | 24 Months n = 164 | |
Antimanic treatment: | ||||||
Types of therapy (n,%): | ||||||
None | 184 (37%) | 0 | 9 (2%)* | 99 (38%) | 0 | 15 (9%)* |
Monotherapy | 191 (38%) | 187 (37%)* | 180 (50%)* | 99 (38%) | 132 (50%)* | 79 (48%)* |
Combination | 129 (26%) | 317 (63%)* | 175 (48%)* | 64 (24%) | 130 (50%)* | 70 (43%)* |
No. of drugs related to the treatment (n,%): | ||||||
None | 184 (37%) | 0 | 9 (2%)* | 99 (38%) | 0 | 15 (9%)* |
1 | 191 (38%) | 187 (37%) | 180 (49%)* | 99 (38%) | 132 (50%) | 79 (48%)* |
2 | 98 (19%) | 241 (48%) | 145 (40%)* | 41 (16%) | 103 (39%) | 56 (34%)* |
3 and + | 31 (6%) | 76 (15%) | 30 (8%)* | 23 (9%) | 27 (10%) | 14 (9%)* |
Types of treatment: (n,% Compared to the population) | ||||||
Lithium | 64 (13%) | 70 (14%) | 57 (16%)* | 36 (14%) | 40 (15%) | 39 (24%)* |
Anticonvulsant | 161 (32%) | 296 (59%) | 187 (51%) | 79 (30%) | 147 (56%) | 72 (44%) |
Atypical antipsychotics. | 75 (15%) | 332 (66%) | 212 (58%) | 36 (14%) | 153 (58%) | 85 (52%) |
Typical antipsychotics | 144 (29%) | 163 (32%) | 77 (21%) | 75 (29%) | 67 (26%) | 34 (21%) |
Compliance: | ||||||
No prescription | 131 (26%) | 2 (1%)* | 60 (23%) | 5 (3%)* | ||
Compliance ≈ 100% | 253 (50%) | 336 (92%) | 147 (56%) | 138 (84%) | ||
Compliance ≈ 50% | 80 (16%) | 20 (5%) | 45 (17%) | 17 (10%) | ||
No compliance | 36 (7%) | 5 (1%) | 8 (3%) | 3 (2%) | ||
Course over 24 months: | ||||||
Maintains (since baseline) (n,% including LTFup): | ||||||
Monotherapy | . | . | 84 (45%)* | 27 (21%)* | ||
Combination | 101 (32%) | 35 (27%) | ||||
The same treatment | 129 (26%)* | 42 (16%)* | ||||
Lithium | 33 (47%) | 17 (43%) | ||||
Anticonvulsant | . | . | 121 (41%)* | . | . | 38 (26%)* |
Atypical antipsychotics. | 139 (42%) | 48 (31%) | ||||
Typical neuroleptics | 34 (21%) | 12 (18%) | ||||
No. of changes of treatment: (n,%) | ||||||
0 | . | . | 62 (17%) | . | . | 33 (20%) |
1 | 59 (16%) | 29 (18%) | ||||
2 | 120 (33%) | 63 (38%) | ||||
3 and + | ||||||
Concomitant treatments: | ||||||
Antidepressants | 139 (28%)* | 75 (15%)* | 98 (27%)* | 138 (53%)* | 129 (49%)* | 91 (55%)* |
Benzodiazepines | 267 (53%)* | 291 (58%)* | 132 (37%) | 177 (68%)* | 187 (71%)* | 74 (45%) |
Anticholinergic drugs | 44 (9%) | 41 (8%) | 21 (6%) | 21 (8%) | 27 (10%) | 10 (6%) |
Hypnotics (others) | 156 (31%) | 199 (39%) | 78 (21%) | 92 (35%) | 97 (37%) | 43 (26%) |
Types of antidepressant: | ||||||
Monotherapy(AD) (n, %): | 134 (96%) | 73 (97%) | 93 (95%) | 135 (98%) | 127 (98%) | 87 (96%) |
IRSS | 104 (78%) | 56 (77%) | 74 (80%) | 96 (71%) | 91 (72%) | 65 (75%) |
Tricyclic | 25 (19%) | 13 (18%) | 17 (18%) | 21 (16%) | 15 (12%) | 16 (18%) |
Others | 5 (4%) | 4 (5%) | 2 (2%) | 18 (13%) | 21 (17%) | 6 (7%) |
Combination of AD (n,%): | 5 (4%) | 2 (3%) | 5 (5%) | 3 (2%) | 2 (2%) | 4 (4%) |